Researchers from the Broad, Abbvie, and Calico Life Sciences have developed a new cancer immunotherapy candidate — now being tested in an early-stage clinical trial — that may provoke a potent response in both cancer and immune cells. Project leaders Robert Manguso and Kathleen Yates, along with first author Hakimeh Ebrahimi Nik, discuss what makes the small molecule inhibitor so exciting.
send comments